Rana Sugars (RANASUG)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at 0.39 times book value, providing a large asset-backing margin of safety.
• Low P/E of 5.16 and PEG of 0.52 suggest statistically cheap valuation if earnings are near cyclical lows.
• Debt-to-equity of 0.43 is moderate and manageable.
• Sales grew 9.99% and latest quarter remained profitable with ₹13 Cr net profit on ₹429 Cr sales.

Concerns

• Profit growth declined 30.21% and Piotroski F-score of 4/9 points to deteriorating fundamentals.
• ROE of 6.80% and ROCE of 7.67% are subpar, reflecting weak capital productivity.
• Zero dividend yield means no income while waiting for value realisation.
• Promoter holding of only 22.64% is low, reducing minority shareholder alignment.

AI Analysis

Let's look at Rana Sugars. The stock trades at ₹13.87 while the stated book value is ₹35.97. That is 39 paise for every rupee of equity—the kind of margin of safety Graham taught. But price is not value; I must ask what those assets earn. ROE is only 6.80% and ROCE is 7.67%. That means management is employing capital at barely above the cost of capital. Sugar is a commodity—no pricing power, no brand lock, no durable moat. The latest quarter had ₹429 Cr sales and just ₹13 Cr profit, a thin net margin of about 3%. Trailing profit is down 30.21%, and the Piotroski F-score of 4/9 tells me the financial picture is deteriorating, not improving. The balance sheet is not alarming: debt/equity of 0.43, and sales grew 9.99%. But I also see zero dividend, so I earn nothing while I wait. Promoter holding is only 22.64%; I prefer insiders with more skin in the game. A P/E of 5.16 looks tempting, but in cyclical sugar, low multiples often appear just before earnings normalize downward. The PEG of 0.52 assumes this earnings decline is temporary—that is an assumption, not a fact. I will not buy a mediocre business merely because it looks statistically cheap. If the book value is real, if sugar cycle turns in their favour, and if management improves capital allocation, this could be an interesting cyclical play. But I need more evidence: better margins, higher return on equity, or signs that minority shareholders are respected. For now, it remains a candidate on my watchlist, not a purchase.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer